# iANTHUS Capital Holdings, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/iANTHUS Capital Holdings, Inc.).

## Overview

iANTHUS CAPITAL HOLDINGS, INC. is a U.S.-based vertically integrated cannabis operator that owns and operates licensed cultivation, processing, and dispensary facilities through its subsidiaries. Its business spans retail dispensaries and production assets across multiple U.S. states, with operations tied to state cannabis licensing and regulatory approvals.

## Products & services

• Licensed cannabis dispensary operations
• Cannabis cultivation facilities
• Cannabis processing and manufacturing
• Wholesale cannabis products
• Retail and branded cannabis product distribution

- **Retail dispensaries** (55%) — State-licensed stores that sell cannabis products directly to consumers.
- **Cultivation** (20%) — Indoor or greenhouse growing operations that produce raw cannabis flower and biomass.
- **Processing and manufacturing** (15%) — Facilities that extract, package, and prepare cannabis products for sale.
- **Wholesale cannabis** (10%) — Sales of cannabis products to other licensed operators and retail channels.

- Licensed cannabis dispensary operations
- Cannabis cultivation facilities
- Cannabis processing and manufacturing
- Wholesale cannabis products
- Retail and branded cannabis product distribution

## Customers

The company sells primarily to adult-use and medical cannabis consumers through its dispensaries, while also serving licensed wholesale and distribution counterparties in states where it can manufacture or distribute products. Its customer base is shaped by state-by-state licensing, so access, product assortment, and store footprint are central to demand capture.

- **Adult-use retail consumers** (primary) — Buy cannabis products from dispensaries for personal consumption and convenience.
- **Medical cannabis patients** (primary) — Purchase regulated cannabis products for therapeutic use in medical markets.
- **Wholesale and licensed operators** (secondary) — Buy cultivated or processed cannabis inventory for resale or further processing.
- **State-regulated distribution channels** (secondary) — Receive manufactured or distributed cannabis products where the company has rights.

- Adult-use cannabis consumers buying flower, vapes, edibles, and concentrates
- Medical cannabis patients seeking regulated products through dispensaries
- Licensed wholesale buyers sourcing cannabis inventory from the company
- State-regulated distribution partners in markets where it has approvals
- Customers are attracted by local access, product availability, and compliance

## Geography

The company operates in seven U.S. states and owns or operates 39 dispensaries plus four cultivation and/or processing facilities. Florida is strategically important because the company has the capacity to own or operate an uncapped number of dispensary licenses there, while other states are constrained by local licensing and regulatory approvals.

- **United States** (100%) — All disclosed operations are in U.S. states; no country-level revenue split was provided.

- Operations are concentrated in seven U.S. states
- 39 dispensaries provide local retail access across multiple markets
- Four cultivation and/or processing facilities support supply and product flow
- Florida is a key market due to uncapped dispensary license capacity
- State licensing determines where the company can expand and operate

## Strategy

The company’s strategy centers on building a multi-state cannabis platform with retail, cultivation, processing, and distribution capabilities under one operating structure. It also emphasizes maintaining access to capital and using asset sales, financing, and operating cash flow to support expansion and obligations.

- **Build a vertically integrated cannabis platform** (medium-term) — Owning retail and production assets helps control supply, margins, and product availability.
- **Expand in licensed state markets** (medium-term) — Cannabis demand is local and regulated, so state approvals determine growth opportunities.
- **Maintain funding flexibility** (short-term) — Capital access is needed for operations, obligations, and future expansion.

- Expand and optimize the multi-state dispensary footprint
- Use cultivation and processing assets to support supply control
- Develop a national retail brand and branded product portfolio
- Preserve liquidity through financing, divestitures, and cash flow
- Operate within state licensing frameworks to secure market access

## Risks

The business is exposed to cannabis-specific regulatory risk because it operates in a federally illegal industry while relying on state licenses and approvals. It also faces financing and liquidity risk, as well as operating restrictions from debt agreements, which can limit flexibility in a capital-intensive and highly regulated market.

- **Federal cannabis illegality** [high] — The company operates in a federally illegal industry, creating legal, banking, and compliance constraints.
- **Liquidity and going-concern risk** [critical] — Operations and capital plans depend on access to additional funding and asset monetization.
- **State licensing and regulatory approvals** [high] — Dispensary, cultivation, and manufacturing rights depend on state-level approvals and compliance.
- **Debt covenant restrictions** [high] — Outstanding debt limits additional indebtedness, liens, dividends, securities issuance, and asset sales.
- **Inventory and asset valuation** [medium] — Cannabis inventory and fixed assets may require write-downs if demand, pricing, or utilization weakens.

- Federal cannabis illegality creates legal and banking constraints
- State licensing limits where the company can operate and expand
- Going-concern and capital-raising risk remain material
- Debt covenants restrict borrowing, dividends, and asset sales
- Inventory valuation and asset impairment can affect reported results

## Accounting

Key accounting judgments include inventory valuation, which the company noted changed as an estimate effective January 1, 2025, and asset impairment or write-downs tied to cannabis operations. The company also operates under Section 280E, which affects tax accounting by limiting deductible expenses, and it uses fair value and debt-related accounting for financing arrangements and related-party balances.

- **Inventory valuation estimate** — Can affect cost of sales and write-downs
- **Section 280E tax accounting** — Raises effective tax burden relative to statutory rates
- **Asset impairment and disposal accounting** — Can materially affect operating results and cash flow presentation
- **Debt and related-party accounting** — Affects interest expense and liabilities

- Inventory valuation estimates can change reported margins and write-downs
- Section 280E limits deductible expenses and affects tax expense
- Asset sales and impairments can create volatile gains or losses
- Debt accretion and extinguishment affect other income and expense
- Related-party interest payable and financing terms require careful disclosure

---

*Last updated: 2026-04-29T05:12:20.857553+00:00*